VERESCA FOXC1 Phase III Triple Negative Breast Cancer Test Data Presented at ASCO 2024
Source: @BreaknNews
SAN DIEGO - May 31, 2024 - -- Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced study results from the Phase III GEICAM/CIBOMA clinical trial involving patients diagnosed with triple-negative breast cancer (TNBC). In the study, statistically significant clinical benefit in terms of improved disease recurrence-free survival (DRFS) was accurately…
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at @BreaknNews